Extended Data Fig. 4: Progression-free survival by MET exon 14 alteration detection in ctDNA.
From: Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
The Kaplan–Meier curves for progression-free survival in patients treated with crizotinib are shown according to detection of MET exon 14 alterations in ctDNA by plasma profiling. Progression-free survival was defined as the time from the date of the first dose of crizotinib to objective disease progression or death from any cause. Hash marks on the survival curve indicate censoring of data. *P value from two-sided log-rank test comparing survival distributions among ctDNA-positive versus ctDNA-negative patients. †HR from Cox proportional hazards regression – assuming proportional hazards, a HR >1 indicates a greater risk of disease progression or death among ctDNA-positive versus ctDNA-negative patients. ctDNA, circulating tumor DNA; HR, hazard ratio; NE, not estimable; PFS, progression-free survival.
